The abstract is read at the publisher; the summary is JClub's.
A single-dose PCV mass-vaccination campaign in a displaced-people camp near Hargeisa, Somaliland, prevents 27% (95% CrI: 20, 34) of severe pneumococcal disease for up to 3 years when vaccinating children <5 years.
- Why it matters: PCVs are rarely used in humanitarian responses, yet pneumococcal disease likely causes substantial burden in crisis-affected populations where routine immunization may be disrupted.
- What they did: The team surveyed pneumococcal carriage, malnutrition, and social contacts near Hargeisa to parameterize a transmission model with migration, then projected campaign impacts using one or two doses and age eligibility <1, 2, 5, 10, or 15 years across crisis settings.
- The result: Expanded age eligibility is needed for comparable protection under higher migration or more contact with unvaccinated hosts; vaccinating <5 years olds is the most efficient, requiring 108 (95% CrI 77–162) doses per severe case prevented, and about 30 million doses would be needed worldwide over 5 years.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.